A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
A Study for Patients with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant
Sponsor: Janssen Research & Development, LLC
Enrolling: Male and Female Patients
IRB Number: AAAS4817
U.S. Govt. ID: NCT03901963
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out whether treatment with daratumumab and lenalidomide will make your Multiple Myeloma better. There are 2 treatment groups in this study. You will either receive lenalidomide alone or both lenalidomide and daratumumab along with medications to take before and after the daratumumab injection.
This study is closed
Investigator
Divaya Bhutani, MD
Do You Qualify?
Are you between the ages of 18 to 79 years of age? Yes No
Do you have newly diagnosed multiple myeloma? Yes No
Have you received consolidation therapy within the last 60 days or are you 60 to 100 days post-transplant? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE